Literature DB >> 33039669

Fasting plasma glucose variability in midlife and risk of Parkinson's disease: A nationwide population-based study.

H S Chung1, J S Lee2, J A Kim3, E Roh3, Y-B Lee3, S-H Hong3, J H Yu3, N H Kim3, H J Yoo3, J A Seo3, S G Kim3, N H Kim3, S H Baik3, K M Choi4.   

Abstract

AIM: Despite the recognized association between type 2 diabetes (T2D) and Parkinson's disease (PD), the implications of glycaemic variability for patients with PD are as yet unknown. For this reason, our study assessed the future risk of incident PD according to visit-to-visit fasting plasma glucose (FPG) variability, as calculated by standard deviation (FPG-SD), coefficient variance (FPG-CV) and variability independent of the mean (FPG-VIM).
METHODS: Using the Korean National Health Insurance Service Health Screening Cohort, 131,625 Korean adults without diabetes were followed. They were divided into a midlife group (age<65 years) and an elderly group (age≥65 years) throughout a median follow-up of 8.4 years.
RESULTS: Adjusted hazard ratios (HRs) were calculated using multivariable Cox proportional-hazards analysis. In the midlife group, HRs for incident PD in the highest quartile of FPG variability (as measured by SD, CV and VIM) were 1.37 [95% confidence interval (CI): 1.09-1.73], 1.33 (95% CI: 1.06-1.68) and 1.35 (95% CI: 1.07-1.70), respectively, vs the lowest variability quartile group. However, while incident PD did not differ according to FPG variability in the elderly group, Kaplan-Meier curves of PD probability in the midlife group showed a progressively increasing risk of PD the higher the FPG variability. According to a multivariable adjusted model, every 1-SD unit increment in glycaemic variability was associated with a 9% higher risk of incident PD in the midlife group.
CONCLUSION: Increased long-term glycaemic variability may be a precipitating risk factor for developing PD in the midlife population without diabetes.
Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Fasting plasma glucose; Glycaemic variability; Midlife; Parkinson's disease; Visit-to-visit

Mesh:

Substances:

Year:  2020        PMID: 33039669     DOI: 10.1016/j.diabet.2020.08.006

Source DB:  PubMed          Journal:  Diabetes Metab        ISSN: 1262-3636            Impact factor:   6.041


  5 in total

1.  Cognition, motor symptoms, and glycolipid metabolism in Parkinson's disease with depressive symptoms.

Authors:  Cong Yao; Lichao Niu; Yun Fu; Xu Zhu; Junfeng Yang; Peng Zhao; Xiaoxiao Sun; Yanyan Ma; Shen Li; Jie Li
Journal:  J Neural Transm (Vienna)       Date:  2021-11-27       Impact factor: 3.850

2.  If Not Insulin Resistance so What? - Comparison of Fasting Glycemia in Idiopathic Parkinson's Disease and Atypical Parkinsonism.

Authors:  Tomasz Chmiela; Julia Węgrzynek; Amadeusz Kasprzyk; Damian Waksmundzki; Dawid Wilczek; Agnieszka Gorzkowska
Journal:  Diabetes Metab Syndr Obes       Date:  2022-05-09       Impact factor: 3.249

3.  Association between vitamin D3 levels and insulin resistance: a large sample cross-sectional study.

Authors:  Zixin Xu; Rongpeng Gong; Gang Luo; Mingxiang Wang; Da Li; Yue Chen; Xiaofang Shen; Xiaoxing Wei; Niran Feng; Shuangquan Wang
Journal:  Sci Rep       Date:  2022-01-07       Impact factor: 4.379

4.  Type 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression.

Authors:  Harneek Chohan; Konstantin Senkevich; Radhika K Patel; Jonathan P Bestwick; Benjamin M Jacobs; Sara Bandres Ciga; Ziv Gan-Or; Alastair J Noyce
Journal:  Mov Disord       Date:  2021-03-08       Impact factor: 9.698

5.  Implications of fasting plasma glucose variability on the risk of incident peripheral artery disease in a population without diabetes: a nationwide population-based cohort study.

Authors:  Hye Soo Chung; Soon Young Hwang; Jung A Kim; Eun Roh; Hye Jin Yoo; Sei Hyun Baik; Nan Hee Kim; Ji A Seo; Sin Gon Kim; Nam Hoon Kim; Kyung Mook Choi
Journal:  Cardiovasc Diabetol       Date:  2022-01-31       Impact factor: 9.951

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.